Whitepaper
Investment Insights
The success of the mRNA-based vaccine for the COVID-19 virus established that mRNA technology is highly effective in improving the body’s immune response. Messenger ribonucleic acid (mRNA) vaccines are faster and easier to mass-produce than traditional vaccines. This feature enabled biopharma companies to invest in and produce mRNA-based COVID-19 vaccines on a large scale, which was necessary to combat the pandemic. But how does one keep fundamentals over frenzy and identify the best-placed beneficiaries? And will the capital raising activity continue to remain that strong?
Key Takeaways:
• The mRNA vaccine technology promises a huge growth potential to biopharma companies.
• After the recent success of mRNA vaccines to fight against the COVID-19 virus, companies are participating in M&A and fundraising activities.
• While mRNA is still in its infancy stage, the fight against COVID-19 has served as a significant testing ground for the technology.
• Companies are now exploring the possibility as well as the benefits of mRNA vaccines to treat other diseases.
To know more...
Authors
Whitepapers
China Real Estate - In Desperate Need of More Policy...
China’s real estate sector has been significantly impacted by the introduction of the three red lines policy, eventually leading to a liquidity crunch...
